The company's principal activity is to develop pharmaceuticals for the treatment of infections, inflammatory and cardiovascular diseases and disorders. The company uses structured-based drug design technologies to develop small-molecule pharmaceuticals for the treatment of diseases and disorders. Some of the projects under development include Neuraminidase Inhibitor, PNP Inhibitor, Tissue Factor, Complement Component C1s inhibitors, Hepatitis C Polymerase Iinhibitors. The company markets its products through collaborators and licensees.
